Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Imatinib dose optimization in CML based on early molecular response
NCT02204722Phase 4Terminated
- Sponsor
- Dong-A ST
- Start
- Oct 2014
- Primary completion
- May 2017
- Countries
- 1
01
Overview
Phase 4, open-label trial in chronic myeloid leukemia (CML) (2 arms), sponsored by Dong-A ST. Primary endpoint: Major Molecular Response rate at 12 months. Started Oct 2014; status: terminated.
02
Conditions
chronic myeloid leukemia (CML)
Beyond the preview
Go deeper on NCT02204722.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02204722.